Abramson JS, Solomon SR, Arnason JE, et al. Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma: Primary Analysis of Phase 3 TRANSFORM Study. Blood. 2022; (doi: 10.1182/blood.2022018730).
The Phase III TRANSFORM study found lisocabtagene maraleucel (liso-cel) to be an effective second-line therapy for primary refractory or early relapsed large B-cell lymphoma, offering significant improvements in event-free survival (EFS), complete response (CR) rate, and progression-free survival (PFS) compared with chemotherapy, with or without autologous stem cell transplantation (ASCT). Researchers randomized 184 adults eligible for ASCT to receive liso-cel (100×106 CAR+ T cells) or standard of care (SOC; 3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). During a median follow-up of 17.5 months, the median EFS — the primary endpoint — was not reached (NR) for liso-cel, compared with 2.4 months EFS for SOC. Liso-cel recipients saw a CR rate of 74% vs. 43% for SOC, while the median PFS was NR for liso-cel and 6.2 months for SOC. The liso-cel cohort did not reach median overall survival (OS), while the SOC cohort had 29.9 months median OS. The median OS was NR for both liso-cel and SOC after adjusting for crossover from SOC to liso-cel. Liso-cel was also well-tolerated, with 1% and 4% of patients in that group experiencing grade 3 cytokine release syndrome and neurological events, respectively, and no grade 4-5 events reported.
Tags: stem cell transplantation, transplantation, Survival, Stem Cells, stem call, Chemo, Transplant, Clinical Research, Autologous, stem cell transplant